Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bone Joint J ; 99-B(11): 1537-1544, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29092996

RESUMEN

AIMS: Calcium sulphate (CaSO4) is a resorbable material that can be used simultaneously as filler of a dead space and as a carrier for the local application of antibiotics. Our aim was to describe the systemic exposure and the wound fluid concentrations of vancomycin in patients treated with vancomycin-loaded CaSO4 as an adjunct to the routine therapy of bone and joint infections. PATIENTS AND METHODS: A total of 680 post-operative blood and 233 wound fluid samples were available for analysis from 94 implantations performed in 87 patients for various infective indications. Up to 6 g of vancomycin were used. Non-compartmental pharmacokinetic analysis was performed on the data from 37 patients treated for an infection of the hip. RESULTS: The overall systemic exposure remained within a safe range, even in patients with post-operative renal failure, none requiring removal of the pellets. Local concentrations were approximately ten times higher than with polymethylmethacrylate (PMMA) as a carrier, but remained below reported cell toxicity thresholds. Decreasing concentrations in wound fluid were observed over several weeks, but remained above the common minimum inhibitory concentrations for Staphylococcus up to three months post-operatively. CONCLUSION: This study provides the first pharmacokinetic description of the local application of vancomycin with CaSO4 as a carrier, documenting slow release, systemic safety and a release profile far more interesting than from PMMA. In particular, considering in vitro data, concentrations of vancomycin active against staphylococcal biofilm were seen for several weeks. Cite this article: Bone Joint J 2017;99-B:1537-44.


Asunto(s)
Antibacterianos/farmacocinética , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Osteomielitis/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Vancomicina/farmacocinética , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/metabolismo , Antibacterianos/uso terapéutico , Sulfato de Calcio , Portadores de Fármacos , Femenino , Infecciones por Bacterias Gramnegativas/metabolismo , Infecciones por Bacterias Grampositivas/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Procedimientos Ortopédicos/instrumentación , Osteomielitis/metabolismo , Estudios Prospectivos , Infecciones Relacionadas con Prótesis/metabolismo , Infecciones de los Tejidos Blandos/metabolismo , Vancomicina/metabolismo , Vancomicina/uso terapéutico
2.
Wiad Lek ; 59(9-10): 727-31, 2006.
Artículo en Polaco | MEDLINE | ID: mdl-17338140

RESUMEN

Linezolid, the first of a new class of antibiotics, the oxazolidinones, is approved for the treatment of Gram-positive bacterial infections, including resistant strains. Linezolid possesses bacteriostatic activity against both antibiotic-susceptible and resistant strains of staphylococci, enterococci and streptococci of relevance to human infection. Clinical trials have confirmed its effectiveness in the treatment of serious infections of skin and soft tissue and the lower respiratory tract. Linezolid has also provided improved outcomes in the treatment of serious vancomycin-resistant entrococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) infections. It is well absorbed with high bioavailability after oral administration and generally well tolerated.


Asunto(s)
Acetamidas/farmacología , Antiinfecciosos/farmacología , Bacterias Grampositivas/efectos de los fármacos , Bacterias Grampositivas/metabolismo , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Oxazolidinonas/farmacología , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Acetamidas/farmacocinética , Antiinfecciosos/farmacocinética , Artritis Infecciosa/tratamiento farmacológico , Enfermedades Óseas Infecciosas/tratamiento farmacológico , Ensayos Clínicos como Asunto/estadística & datos numéricos , Humanos , Linezolid , Pruebas de Sensibilidad Microbiana , Oxazolidinonas/farmacocinética , Neumonía/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/metabolismo
3.
Biomaterials ; 25(18): 4037-45, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15046894

RESUMEN

Particle-induced macrophage activation, mainly by UHMWPE wear, has been recognized as the biological mechanism leading to periprosthetic bone resorption, which is responsible for the loosening of the total hip replacements (THR). Ceramic-on-ceramic implants have been advocated as a means of reducing wear products. Many studies investigated the effect of alumina (Al(2)O(3)) particles on monocytes/macrophages, but only limited information are available on their participation to bone turnover. An in vitro model was performed to investigate how Al(2)O(3) and UHMWPE particles may influence the osteoblast-osteoclast interaction: human osteoblasts (HOB) were obtained from trabecular bone, while osteoclasts were derived from peripheral blood mononuclear cells (PBMC) of healthy donors. The amount of IL6, TNF alpha, GM-CSF, and other factors acting on the bone turnover, i.e. the 'receptor activator of NF kappa B' ligand (RANKL) and osteoprotegerin (OPG), was detected in culture medium of particle-challenged HOB (HOB-CM). The Al(2)O(3) and UHMWPE particles did not affect either cell viability or TNF and GM-CSF release, while the increase in IL6 release seemed to be dependent on the particle concentration. UHMWPE increased the release of RANKL from HOB, while OPG and OPG-to-RANKL ratio were significantly inhibited. The ability of HOB-CM to promote osteoclastogenesis was tested via osteoblast/monocyte cooperation: after seven days of culture UHMWPE HOB-CM induced a large amount of multinucleated TRAP-positive giant cells, as well as significantly reduced the amount of IL6, GM-CSF and RANKL in the supernatant. With regard to the inductive effect on the osteoclastogenesis, our results show that the Al(2)O(3) wear debris are less active.


Asunto(s)
Óxido de Aluminio/química , Técnicas de Cocultivo/métodos , Cuerpos Extraños/patología , Osteoblastos/patología , Osteoclastos/patología , Polietilenos/química , Materiales Biocompatibles/química , Diferenciación Celular , Supervivencia Celular , Células Cultivadas , Citocinas/metabolismo , Análisis de Falla de Equipo , Cuerpos Extraños/etiología , Cuerpos Extraños/metabolismo , Humanos , Ensayo de Materiales , Osteoblastos/metabolismo , Osteoclastos/metabolismo , Tamaño de la Partícula , Falla de Prótesis , Infecciones Relacionadas con Prótesis/etiología , Infecciones Relacionadas con Prótesis/metabolismo , Infecciones Relacionadas con Prótesis/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA